Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide
NCT ID: NCT00806013
Last Updated: 2010-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
36 participants
OBSERVATIONAL
2008-08-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
NCT06256419
Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM
NCT05037045
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
NCT01619332
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
NCT02916706
Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects
NCT01690169
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
CYP2C9\*1/\*1 and CYP2C19\*1/\*1 alleles carrier
No interventions assigned to this group
2
CYP2C19 PMs (CYP2C19\*2/\*2, CYP2C19\*2/\*3 or CYP2C19\*3/\*3)
No interventions assigned to this group
3
CYP2C9\*1/\*3 and CYP2C19\*1/\*1 alleles carrier
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study
21 Years
27 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Sciences
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Tan
Role: PRINCIPAL_INVESTIGATOR
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The second hospital to Liaoning University of TCM
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Our organization
Chinese Academy of Sciences
Liaoning University of TCM
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SIMM-080601
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.